

E-Cigarette Use, Cigarette Use, and Sex Modify the Nasal Microbiome and Nasal Host-Microbiota Interactions

Elise Hickman

The University of North Carolina at Chapel Hill

Andrew Hinton

The University of North Carolina at Chapel Hill

Bryan Zorn

The University of North Carolina at Chapel Hill

Meghan E. Rebuli

The University of North Carolina at Chapel Hill

Carole Robinette

The University of North Carolina at Chapel Hill

Matthew Wolfgang

The University of North Carolina at Chapel Hill

Peter J. Mucha

The University of North Carolina at Chapel Hill

Ilona Jaspers (✉ ilona_jaspers@med.unc.edu)

The University of North Carolina at Chapel Hill <https://orcid.org/0000-0001-8728-0305>

Research

Keywords: e-cigarettes, cigarettes, nasal microbiome, host-microbiota interactions, biomarkers

Posted Date: August 3rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-725763/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Title:** E-Cigarette Use, Cigarette Use, and Sex Modify the Nasal Microbiome and Nasal Host-
2 Microbiota Interactions

3
4 **Authors:** Elise Hickman^{1,2*}, Andrew Hinton^{3,4,*}, Bryan Zorn⁵, Meghan E. Rebuli^{1,2}, Carole
5 Robinette¹, Matthew Wolfgang^{5,6}, Peter J. Mucha^{3,7}, Ilona Jaspers^{1,2#}

6 *These authors contributed equally to the published work.

7 # Corresponding author

8
9 **Affiliations:**

10
11 ¹ Center for Environmental Medicine, Asthma, and Lung Biology

12 ² Curriculum in Toxicology & Environmental Medicine

13 ³ Curriculum in Bioinformatics and Computational Biology

14 ⁴ UNC Food Allergy Initiative, School of Medicine

15 ⁵ Marsico Lung Institute

16 ⁶ Department of Microbiology and Immunology

17 ⁷ Department of Mathematics and Department of Applied Physical Sciences

18 University of North Carolina, Chapel Hill, NC, United States

19
20 **Addresses:**

21
22 Elise Hickman; ehickman@email.unc.edu; 116 Manning Drive, 4310 Mary Ellen Jones
23 Building, Chapel Hill, NC 27599

24
25 Andrew Hinton; andrew84@email.unc.edu; 116 Manning Drive, Chapel Hill, NC 27599

26
27 Bryan Zorn; bryanzorn@gmail.com; 125 Mason Farm Road, 7105 Marsico Hall, Chapel Hill,
28 NC 27599

29
30 Meghan E. Rebuli; meradfor@email.unc.edu; 116 Manning Drive, 4310 Mary Ellen Jones,
31 CB#7325, Chapel Hill, NC 27599

32
33 Carole Robinette; carole_robinette@med.unc.edu; 104 Mason Farm Road, Chapel Hill, NC
34 27599

35
36 Matthew Wolfgang; matthew_wolfgang@med.unc.edu; 125 Mason Farm Road, 7105 Marsico
37 Hall, Chapel Hill, NC 27599

38
39 Peter J. Mucha; peter.j.mucha@dartmouth.edu; 27 N. Main Street, 6188 Kemeny Hall, Hanover
40 NH, 03755

41
42 Ilona Jaspers; ilona_jaspers@med.unc.edu; 116 Manning Drive, Chapel Hill, NC 27599

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75

Abstract

Background: E-cigarettes are often perceived as safer than cigarettes, but previous research suggests that e-cigarettes can alter respiratory innate immune function. The respiratory microbiome plays a key role in respiratory host defense, but the effect of e-cigarettes on the respiratory microbiome has not been studied.

Results: Using 16S rRNA gene sequencing on nasal epithelial lining fluid samples from adult e-cigarette users, smokers, and nonsmokers, followed by novel computational analysis of pairwise log ratios, we determined that e-cigarette use and smoking causes differential respiratory microbiome dysbiosis, which was further affected by sex. We also collected nasal lavage fluid for analysis of immune mediators associated with host-microbiota interactions. Our analysis identified disruption of the relationships between host-microbiota mediators in the nose of e-cigarette users and smokers, which is indicative of disrupted respiratory mucosal immune responses.

Conclusions: Our data indicate that e-cigarette use, cigarette use, and sex modify the nasal microbiome and nasal host-microbiota interactions. Our approach also provides a novel platform that robustly identifies host immune dysfunction caused by e-cigarette use or smoking.

Keywords: e-cigarettes, cigarettes, nasal microbiome, host-microbiota interactions, biomarkers

Background

Approximately 7 million adults and more than 3.5 million youth are current electronic cigarette (e-cigarette) users [1-3]. E-cigarettes heat and aerosolize e-liquids containing nicotine

76 and flavorings dissolved in humectants propylene glycol and glycerin. E-cigarette use has been
77 steadily increasing over the past decade, especially among teenagers and young adults, reversing
78 the previous decline in youth tobacco use [3, 4]. Public health crises, such as the outbreak of e-
79 cigarette and vaping-associated lung injury in 2019-2020 and the ongoing SARS-CoV-2 global
80 pandemic, highlight the importance of research examining the effects of e-cigarettes on
81 respiratory immune function [5, 6].

82 There is emerging evidence that e-cigarettes disrupt respiratory innate immunity.
83 Previous work has demonstrated the potential for e-cigarette toxicity and impairment of
84 respiratory immune defense using *in vitro* and *in vivo* models as well as in samples from human
85 subjects [7-12]. For example, e-cigarette users have altered markers of innate immune responses
86 in induced sputum and bronchoalveolar lavage fluid in comparison with smokers and
87 nonsmokers [8, 12] and chronic e-cigarette exposure in mice can dysregulate endogenous lung
88 lipid homeostasis and innate immunity [11, 13]. *In vitro* studies have demonstrated that e-liquids,
89 e-cigarette aerosols, and their components can impair the function of ciliated airway cells and
90 respiratory immune cells [9, 14-18]. Furthermore, e-cigarette exposure has been shown to
91 enhance bacterial virulence and adhesion to airway cells [19, 20], suggesting that e-cigarette
92 exposure may impact the respiratory microbiome. However, the effects of e-cigarette use on the
93 respiratory microbiome in humans have not been evaluated.

94 The respiratory microbiome includes distinct communities of microbiota along the length
95 of the respiratory tract [21]. Similar to microbial communities at other body sites, respiratory
96 microbiota interface with the host immune system, and dysbiosis of the respiratory tract
97 microbiome has been associated with diseases, including cystic fibrosis, chronic obstructive
98 pulmonary disease, asthma, and chronic rhinosinusitis, as well as with disease exacerbations and

99 smoking cigarettes [21-24]. Sampling the nasal microbiome is straightforward in contrast to the
100 lower airway microbiome, which is easily contaminated with oral microbiota during specimen
101 collection [25]. In addition, the nose is an important gatekeeper in the respiratory tract, as
102 potential pathogens must often colonize this region before progressing to the lower respiratory
103 tract [21]. This role has become even more clear and relevant with the emergence of SARS-CoV-
104 2, with recent studies showing associations between the nasal microbiome and SARS-CoV-2
105 infection [26, 27]. Of note is that dysbiosis of the nasal microbiome specifically has been
106 associated with smoking cigarettes [23], and gene expression and histopathological changes due
107 to smoking are similar in the nasal and lower airway epithelium [7], supporting the use of the
108 nasal microbiome for studying the effects of environmental exposures on the respiratory
109 microbiome.

110 Mechanistic study of the human microbiota is an important focus when studying the
111 human microbiome, where identifying microbes associated with disease is paramount [28]. To
112 uncover complex interactions in microbiome association studies changes to classical statistical
113 methods are required [29]. In addition, computational methods that robustly integrate disparate
114 data types with 16S microbiome data for association testing have been limited [30]. In particular,
115 microbiome datasets have interspecies interactions, small sample sizes, high dimensionality
116 (where the number of features greatly exceed the number of samples), are sparse (where the data
117 matrix contains many zeroes), and when converted to relative abundance are compositional,
118 meaning the total number of reads is not informative [31]. Combined, these challenges
119 significantly confound the multivariate integrative analysis required to improve our
120 understanding of host-microbiome interactions. Thus, novel analytical tools are necessary to
121 uncover true signals hidden within small sample size microbiome data.

122 In this study, we sampled the nasal microbiomes of smokers, nonsmokers, and e-cigarette
123 users using a non-invasive absorptive strip to collect nasal epithelial lining fluid. We then used
124 high-throughput sequencing of the bacterial 16S rRNA gene from the strips to identify bacteria
125 present and analyze the bacterial composition of the nasal microbiome in our subjects. Because
126 these microbial communities are composed of highly interdependent taxa that have complex
127 interaction patterns, multivariate data analysis is critical to extract biologically relevant
128 information.

129 Here, we leverage Selection Energy Permutation [32], a novel multivariate association
130 test that simultaneously tests associations while identifying robust subsets of pairwise log ratios
131 in the setting of high-dimensional, low sample size data. These reduced subsets are then used to
132 integratively analyze nasal microbiome and matched cell-free nasal lavage fluid mediator data to
133 determine: 1) whether there were significant compositional differences in the nasal microbiomes
134 of E-cigarette users, smokers, and nonsmokers, 2) whether levels of nasal lavage fluid (NLF)
135 mediators are significantly different in e-cigarette users and smokers in comparison with
136 nonsmokers, and 3) whether changes in levels of these mediators correlate with nasal
137 microbiome dysbiosis. Our data demonstrate nasal microbiome dysbiosis and unique networks of
138 host-microbiota mediators in e-cigarette users and smokers in comparison with nonsmokers. This
139 is indicative of disrupted respiratory mucosal immune responses in these groups and potentially
140 increased susceptibility to infection by specific bacterial taxa. We also observed significant sex
141 differences in the nasal microbiome, highlighting the importance of including sex as a biological
142 variable in nasal microbiome studies.

143
144
145
146

147 **Methods**

148

149 *Subject recruitment.* Nasal epithelial lining fluid (NELF) strips, nasal lavage fluid (NLF), and
150 venous blood were obtained from healthy adult human e-cigarette users, smokers, and
151 nonsmokers as described previously (**Table 1**)[33], forming our exposure groups. Inclusion
152 criteria were healthy adults age 18-50 years who are either nonsmokers not routinely exposed to
153 environmental tobacco smoke, active regular cigarette smokers, or active e-cigarette users.
154 Active cigarette smoking and e-cigarette use were determined as described previously [7].
155 Exclusion criteria were current symptoms of allergic rhinitis (deferred until symptoms resolve),
156 asthma, FEV₁ less than 75% predicted at screen, bleeding disorders, recent nasal surgery,
157 immunodeficiency, current pregnancy, chronic obstructive pulmonary disease, cardiac disease,
158 or any chronic cardiorespiratory condition. After the consent process was completed, a medical
159 history and substance use questionnaire was obtained, and subjects were issued a diary to
160 document smoking/vaping for up to 4 weeks, after which they returned for sample collection. E-
161 cigarette users averaged less than 1.5 cigarettes/day in their smoking/vaping diaries, while
162 cigarette users ranged from 4.93-20 cigarettes per day in their diaries. To compare demographic
163 characteristics between subjects in the different exposure groups, age, BMI, and serum cotinine
164 levels were tested for normality using the Shapiro-Wilk test, and groups were compared using
165 the Kruskal-Wallis test followed by the Steel-Dwass method for non-parametric multiple
166 comparisons (analogous to a one-way ANOVA with Tukey's HSD for parametric data).

167

168 *Serum Cotinine Measurement.* Venous blood was collected in BD Vacutainer serum-separating
169 tubes (Fisher Scientific, Waltham, MA) and allowed to clot for a minimum of 15 minutes at
170 room temperature. The blood was then centrifuged at 1200 x g for 10 minutes, and the serum

171 layer was transferred to a fresh tube and stored at -80°C until samples were collected from all
172 subjects. Serum was assayed for cotinine, a metabolite of nicotine that can be measured as a
173 biomarker of nicotine consumption, using a commercially available ELISA kit (Calbiotech,
174 Mannheim, Germany) per manufacturer's instructions. Absorbance was read on a CLARIOstar
175 plate reader (BMG Labtech, Ortenberg, Germany). The limit of quantification for serum cotinine
176 was 5 ng/mL. For samples below the limit of detection, a value of zero was assigned. Serum was
177 not available for one subject in the cohort.

178

179 *NELF Strip Metagenomic Sequencing.* DNA was extracted from whole NELF strips using the
180 Powersoil DNA Isolation Kit (MoBio Laboratories). Sequencing libraries were prepared as
181 previously described [34]. Samples were sequenced on an Illumina MiSeq kit version V3 2x300
182 paired end over the V3-V4 bacterial 16S gene. Raw sequencing data were demultiplexed and
183 processed to generate a table of operational taxonomic units (OTUs). Specific primer schema,
184 qPCR data, and the OTU table (having at least 10 sequences per OTU across all samples) are
185 provided in the supplement. Raw sequence data have been uploaded under the BioProject
186 accession number PRJNA746950 within the Sequence Read Archive.

187

188 *NLF Processing and Soluble Mediator Measurement.* Cell-free nasal lavage fluid was obtained
189 via processing of raw nasal lavage fluid as described previously [35]. Briefly, raw nasal lavage
190 fluid from each nostril was pooled and centrifuged at 500x g through a 40 µm strainer for 10
191 minutes. Supernatant (cell-free NLF) was collected and stored at -80°C until samples were
192 collected from all subjects. Cell-free NLF was assayed for mediators of host-microbiota
193 interaction (neutrophil elastase, immunoglobulin A (IgA), lactoferrin, lysozyme, interleukin 8

194 (IL-8), alpha-defensin 1, beta-defensin 1, beta-defensin 2, cathelicidin (LL-37)) using
195 commercially available ELISA kits per manufacturer's instructions as described in
196 Supplementary Table 1. Absorbance was read on a CLARIOstar plate reader. For samples below
197 the limit of detection, a value of ½ the lowest standard was assigned. Cell-free nasal lavage fluid
198 was not available for one subject in the cohort (Figure S1).

199

200 *Sequencing Data Processing and Filtering.* Five samples were removed from the dataset due to a
201 low number of reads (Figure S1). A spiked pseudomonas positive control was identified
202 correctly as pseudomonas. To control for potential contamination on the NELF strips, the
203 decontam R package was used to remove contaminants [36]. This package uses an algorithm that
204 takes into account the relative abundance of OTUs in samples and controls to remove the most
205 likely contaminants and has been shown useful for respiratory samples [37]. This reduced the
206 number of OTUs from 5346 to 4677. Alpha diversity measures (Observed, Chao1, ACE,
207 Shannon, Simpson, Fisher) were calculated using the phyloseq R library before trimming OTU
208 counts less than 5 for downstream analysis. This brought the number of OTUs to 3059 for
209 downstream analysis.

210

211 *Alpha diversity.* Shannon and Simpson diversity indices were computed for each sample.
212 Diversity indices were tested for normality using the Shapiro-Wilk test and further statistical
213 tests to compare groups were carried out using the appropriate parametric (two-tailed t-test,
214 ANOVA) or non-parametric (Kruskal-Wallis, Steel Dwass) tests. These analyses were performed
215 using JMP Pro 14 and GraphPad Prism 8.

216

217 *Nasal Microbiome Compositional Data Analysis*. To limit spurious findings and because
 218 absolute sequencing counts are uninformative [31, 38, 39], compositional data analysis
 219 (CoDA)[40] was carried out on the OTU count table after aggregating OTUs ($O = 3059$) by
 220 family (min. level assigned) and genera (max level assigned) and removing taxa not present in at
 221 least 20% of samples. The 20% sparsity threshold was selected to maximize class-specific
 222 information (Sex, Exposure group) while ensuring the microbial signatures were robust and
 223 contained minimal noise due to excessive sparsity. After aggregating OTUs, we define the taxa
 224 count matrix, $\mathbf{X} \in \mathbb{R}^{n \times p}$, with $n = 62$ samples and $p = 143$ taxa. The closure operator, $C[\cdot]$, was
 225 then used to map the count data of each element x_{ij} of \mathbf{X} onto its corresponding coordinate on
 226 the unit-sum simplex, defining $\mathbf{X}' = C[\mathbf{X}]$ in terms of matrix elements as

227

$$228 \quad x'_{ij} = (C[\mathbf{X}])_{ij} = \frac{x_{ij}}{\sum_{k=1}^p x_{ik}}$$

229

230 Because the presence of zeros is a major limitation of the log ratio transformation essential to
 231 CoDA, all zeroes must be robustly imputed to non-zero values. To overcome this we use the
 232 ratio-preserving multiplicative replacement strategy which has been shown to have several
 233 theoretical advantages over simple additive replacement [41]. We set the δ imputed values to a
 234 single constant equal to the smallest nonzero value encountered in \mathbf{X}' . From this, we impute
 235 zeros and replace \mathbf{X}' with \mathbf{Z} defined in matrix elements as:

236

$$237 \quad z_{ij} = \begin{cases} \delta & , \quad x'_{ij} = 0 \\ \left(1 - \sum_{k|x_{ik}=0} \delta\right) x'_{ij} & , \quad x'_{ij} > 0 \end{cases}$$

238

239 *Partial redundancy analysis to remove variation due to Sex.* To remove the significant effect of
240 Sex (which otherwise obscures the exposure group effect) on \mathbf{Z} , partial Redundancy Analysis
241 (pRDA) [42] was used. Here we encode the Sex variable into the design matrix \mathbf{S} . Additionally,
242 to ensure multiple regression computations used in pRDA are performed on symmetric vectors in
243 real space that preserves the inter-sample Euclidean distances, a center log ratio (clr)
244 transformation was applied [40] to \mathbf{Z} , defining the clr values \mathbf{C} for each sample as $\mathbf{c}_i = [c_1, \dots, c_p]$
245 such that:

246

$$247 \quad c_{ij} = \log\left(\frac{z_j^i}{G_i}\right) \text{ where } G_i = \left(\prod_j z_{ij}\right)^{\frac{1}{p}}$$

248

249 With \mathbf{C} defined, pRDA was carried out in the vegan R package. [43] Multivariate linear
250 regression of \mathbf{C} on \mathbf{S} (i.e. computed as a series of multiple linear regression on individual
251 features) was used to produce the fitted values $\hat{\mathbf{C}}$. To remove the Sex effect as in pRDA, the
252 adjusted values of \mathbf{C} were computed by $\mathbf{P} = \mathbf{C} - \hat{\mathbf{C}}$ where $\hat{\mathbf{C}}$ contains all variation attributable to
253 Sex. With \mathbf{P} defined in Euclidean coordinates which are not suitable for downstream pairwise
254 log ratio transformations, an inverse clr transformation was applied to map the adjusted
255 coordinates back to the unit-sum simplex. The Sex adjusted relative abundance matrix \mathbf{M} with
256 elements m_{ij} is computed as:

257

$$258 \quad m_{ij} = \frac{\exp(p_{ij})}{\sum_{k=1}^p \exp(p_{ik})}$$

259

260 *Nasal Microbial Signature identification using Selection Energy Permutation.* To identify
261 microbial log ratio signatures in the setting of high-dimensional low sample size data we utilized
262 the recently developed Selection Energy Permutation (SelEnergyPerm) method, which has been
263 shown to have increased statistical power over several existing multivariate hypothesis testing
264 methods under hypothesis testing settings like this.[32] The SelEnergyPerm method
265 simultaneously selects a reduced subset of log ratios while maximizing the association between
266 groups. Let the group distributions be defined as $X \in \mathbb{R}^{n \times f}$ and $Y \in \mathbb{R}^{m \times f}$. In this work, we
267 use SelEnergyPerm with the energy statistic (E-statistic)[44] defined by

268

$$269 \quad \mathcal{E}_{n,m}(X, Y) = 2A - B - C,$$

270 where A, B, and C are specified, in terms of the vectors of \mathbb{R}^f indexed by sample, by

$$271 \quad A = \frac{1}{nm} \sum_{i=1}^n \sum_{j=1}^m \|\mathbf{x}_i - \mathbf{y}_j\|, \quad B = \frac{1}{n^2} \sum_{i=1}^n \sum_{j=1}^n \|\mathbf{x}_i - \mathbf{x}_j\|, \quad C = \frac{1}{m^2} \sum_{i=1}^m \sum_{j=1}^m \|\mathbf{y}_i - \mathbf{y}_j\|$$

272 From this, the pooled multi-class (#classes (c) ≥ 2) E-statistic becomes

$$273 \quad S = \sum_{1 \leq j < k \leq c} \left(\frac{n_j + n_k}{2N} \right) \left[\frac{n_j n_k}{n_j + n_k} \mathcal{E}_{n_j, n_k}(X_j, X_k) \right]$$

274 The pooled E-statistic is then maximized using forward selection on a subset selected from the
275 full set of pairwise log ratios to explain maximal variation when compared to the full set of
276 pairwise log ratios. Similar to the approach in Greenacre et al. [45], the reduced subset of log
277 ratios are selected from the $\frac{p(p-1)}{2}$ 2-dimensional feature space (all pairs). However, there are
278 p^{p-2} possible ways to select a subset of log ratios that explain the total log ratio variance. To

279 overcome this, SelEnergyPerm scores each log ratio using the differential compositional
280 variation scoring method and then iteratively computes acyclic subsets of log ratios [32], with
281 permutation testing via Monte Carlo sampling [46] to assess the significance and prevent
282 overfitting of the log ratio signature. Specifically, given a log ratio signature discovered with true
283 labels, SelEnergyPerm tests if the observed pooled E-statistic (S^*) is more extreme than E-
284 statistics sampled from the permutation distribution of log ratio signatures selected under random
285 labels (S_i , indexing different random-label samples). With γ such E-statistics randomly sampled
286 from the permutation distribution the one-sided p-value becomes

287

$$288 \quad \hat{p} = \frac{1 + \sum_{i=1}^{\gamma} I(S_i > S^*)}{\gamma + 1}$$

289

290 As expected, we find that removing large numbers of uninformative features increases statistical
291 power in the high-dimensional low-sample-size setting. To identify the Sex nasal microbial
292 signatures in this study we utilized \mathbf{Z} with labels = *Sex* and for the Exposure group microbial
293 signature we utilized \mathbf{M} with labels = *Subject Group*. Using these data, we applied the
294 SelEnergyPerm method with default settings using 200 permutations. Additionally, to reduce
295 noise from sparse features, we further reduced taxa included in the analysis by first identifying
296 the number of taxa to include in the microbial signature. We tested the following subset
297 sizes: [5,10,20,40,60,80,100]. Applying the SelEnergyPerm method on each subset and
298 normalizing the energy statistic [44] we selected the subset that maximized the normalized
299 pooled energy statistic ([Figure S2](#)) and then tested if the observed S^* was more extreme than
300 random. In this way, we increase the statistical power of our analysis and reduce the chance of

301 overfitting. While this is good for identifying associations, it can come at the expense of reduced
302 overall discriminatory potential.

303

304 *Network Visualization of Microbial signature.* To visualize the microbial log ratio signatures, we
305 constructed undirected graphs connecting the key taxa (vertices/nodes) by edges representing the
306 formation of a ratio between two taxa with edge weight corresponding to the between-group
307 Kruskal-Wallis H-statistic. While the full log ratio structure is directed in distinguishing
308 numerators from denominators, directedness in the visualizations used here does not
309 fundamentally change our interpretation. Graphs were visualized using Gephi [47] and R-igraph
310 [48].

311

312 *Multivariate statistical test for microbial signals.* To confirm associations between microbial log
313 ratio signatures and Sex/Exposure group multivariate hypothesis testing was done using
314 permutational multivariate analysis of variation [49] and implemented using the R vegan
315 package [43]. Unsupervised lower-dimensional projections of samples and group centroids were
316 done using principal coordinate analysis (PCoA) and were implemented using the R stats
317 package.

318

319 *Partial Least Squares Discriminate Analysis.* We utilized partial least squares discriminate
320 analysis (PLS-DA) [50, 51], a versatile multivariate statistical regression technique, to model and
321 understand the relationship between Sex/Exposure group to their microbial signatures. Shown to
322 have reliable performance on compositional and genomic datasets [52, 53], PLS-DA models
323 perform classification, inference, and are inherently linear thus offering improved model

324 interpretability. We specified a priori the number of PLS-DA components (ncomp) as follows:
325 for the between Sex nasal microbial signature, ncomp = 1; for the between Exposure group nasal
326 microbial signature, ncomp = 2. Model fitting was done using the R caret [54] *plsda* function,
327 with latent space projections and loadings extracted from the final models fit using all samples
328 using R caret [54]. PLS-DA biplots were created by scaling and superimposing the loading
329 vectors onto the score coordinates extracted from the final fitted model. PLS-DA biplots were
330 visualized using the R ggplot2 package [55].

331
332 *Receiver operating characteristic curve analysis and PLS-DA performance metric.* To
333 understand how well the binary PLS-DA models discriminate between Sex using the nasal
334 microbiome signature, we utilized the area under the receiver operating characteristic metric,
335 AUC, which represents the probability that a randomly selected instance of class 1 will be ranked
336 higher than a randomly selected instance of class 2 [56]. Additionally, to understand the
337 discriminatory potential of the ternary PLS-DA Exposure group models, the multi-class AUC
338 metric was used. The multi-class AUC generalizes binary AUC through pairwise class AUC
339 averaging and has the useful property of being independent of cost and priors as in AUC while
340 having a similar interpretation to misclassification rate [57]. AUC metrics were estimated using
341 repeated k-fold cross-validation [58]. The R pROC package [59] was used to compute all AUC
342 metrics. ROC curves, which graph the false positive and true positive rate of a classifier over a
343 range of thresholds, were computed using the R pROC package [59] and visualized using the R
344 ggplot2 package [55].

345

346 *NLF mediator and microbiome data integration.* We define the nasal lavage data matrix, $\mathbf{L} \in$
 347 $\mathbb{R}^{n \times f}$, where $n = 66$ samples and $f = 7$ mediators. Treating the data as relative such that sample-
 348 wise absolute concentrations in our study are considered unimportant (**Figure S3A**), zeroes were
 349 imputed after applying the closure operator to \mathbf{L} as described in our compositional data analysis
 350 methods. From this, we define $\mathbf{L}' \in \mathbb{R}^{n \times k}$, with $k = 21$, to include all pairwise log ratios from \mathbf{L} .
 351 To remove uninformative NLF mediators, we computed the differential compositional variation
 352 (DCV) score [32] and assigned each NLF mediator log ratio a score by averaging the within-fold
 353 DCV score using 20 repeats of 10-fold cross-validation. NLF log ratios with a DCV score < 0
 354 were considered uninformative and were removed (**Figure S3B**). From this \mathbf{L}' was reduced to $\hat{\mathbf{L}} \in$
 355 $\mathbb{R}^{n \times k}$ where $k=4$ (**Figure S3C**) log ratios. To test for univariate associations between NLF
 356 mediator log ratios and Exposure group the Kruskal-Wallis test was applied followed by
 357 pairwise Wilcoxon rank-sum testing if $\alpha < 0.05$. The nasal microbiome signal was obtained by
 358 applying the SelEnergyPerm method to \mathbf{M} to get $\hat{\mathbf{M}} \in \mathbb{R}^{n \times r}$ where $n = 62$ and $r = 9$ log ratios.
 359
 360 Concatenating these data, we define the integrated NLF mediator and nasal microbiome matrix
 361 as $\mathbf{D} \in \mathbb{R}^{n \times f}$ where $n = 61$ (6 samples were removed due to either missing nasal microbiome or
 362 NLF data) and $f = 13$ (4-nasal lavage and 9 microbiome log-ratio features). Exposure group
 363 discrimination was estimated separately for each of $\hat{\mathbf{L}}$, $\hat{\mathbf{M}}$, and \mathbf{D} using multi-class AUC from 50
 364 repeats of 10-fold cross-validation using 2-component PLS-DA models. Multi-class AUC
 365 estimates using $\hat{\mathbf{L}}$, $\hat{\mathbf{M}}$, and \mathbf{D} were compared between groups using the non-parametric Wilcoxon
 366 rank-sum test.

367

368 *Nasal NLF mediator and microbiome association analysis*

369 A final 2-component PLS-DA model to discriminate between exposure groups was fit to $\hat{\mathbf{M}}$.
370 Using dimensionality reduction inherent to PLS-DA, the first PLS-DA component (explaining
371 the most variation) was extracted as a latent variable for further analysis. Pearson's correlation
372 coefficients (PCC) and subsequent p-values were computed between the first PLS-DA
373 component and \mathbf{L}' represent the reduced nasal microbiome exposure group signature. PCC p-
374 values, adjusted for multiple comparisons (q-value) using the Benjamini-Hochberg (BH)
375 correction,[60] were considered significant if $q \leq 0.10$. These analyses were carried out using
376 the R stats and caret packages.

377

378 *Between Exposure group Correlation analysis.* Partitioning the samples of \mathbf{D} into 3 matrices
379 based on exposure group (nonsmokers, e-cig users, or smokers), we calculate all pairwise PCC
380 and p-values between features for each group. We also report q-values after adjusting for
381 multiple comparisons within each group using the BH method. Correlations were considered
382 significant if $q \leq 0.10$. Significant PCC within each subject were then aggregated across all
383 exposure groups and visualized as a graph using the R igraph package [48].

384

385 *Confidence Intervals and univariate statistical test for log ratios.* Log ratio 95% confidence
386 interval estimates were calculated by

387

$$388 \quad CI_i = \bar{x}_i \pm 1.96 \frac{s_i}{\sqrt{n}}$$

389

390 where for the i th log ratio, \bar{x}_i = sample mean, s_i = sample standard deviation and n =number
391 samples. Log ratios with confidence intervals bounds that do not include 0 are interpreted as

392 enriched on average for the numerator if $\bar{x} > 0$ or denominator if $\bar{x} < 0$. The Kruskal-Wallis
393 and Wilcoxon rank-sum test were used for univariate comparisons of log ratios between Sex or
394 Exposure groups. Moreover, p-values were adjusted for multiple comparisons using the BH
395 correction using the R stats library and are reported as q-values.

396

397 **Results**

398

399 *Subject Demographics*

400

401 Demographic, questionnaire, and smoking/vaping diary data are summarized in [Table 1](#). The
402 study cohort was comprised of 30% nonsmokers (n = 20), 42% e-cigarette users (n = 28), and
403 28% smokers (n = 19) with at least n = 8 per sex within each exposure group. E-cigarette users
404 were significantly younger (26.39 ± 1.44) than nonsmokers (30.75 ± 1.32) and smokers ($31.89 \pm$
405 1.91) ($p < 0.05$). BMI did not differ significantly between the exposure groups. Questionnaires
406 and smoking/vaping diaries were completed for 95% (19/20) of nonsmokers and 100% of e-
407 cigarette users and smokers. However, there was variability in the completeness of diaries filled
408 out by e-cigarette users, particularly for the e-cigarette use parameters (mL/day, puffs/day,
409 nicotine concentration, flavor, device). Cigarette users smoked an average of 12.68 ± 0.96
410 cigarettes per day, whereas 25% (7/28) of e-cigarette users smoked a cigarette during the diary
411 period with an average of 0.14 ± 0.07 cigarettes per day, while 13 e-cigarette users reported puffs
412 per day and 16 reported mL e-liquid/day and e-liquid nicotine concentration in mg/mL. These e-
413 cigarette users averaged 53.90 ± 16.54 puffs/day, 3.60 ± 0.70 mL of e-liquid, and 19.43 ± 4.92
414 mg/mL nicotine in e-liquids. One smoker reported vaping on one day of the diary, which is the

415 reason for the non-zero values for e-cigarette use parameters in the smoker category.
416 Nonsmokers did not report previous cigarette smoking or marijuana use, whereas 79% (22/28) of
417 e-cigarette users were former cigarette smokers, while 14% (4/28) of e-cigarette users and 21%
418 (4/19) of smokers reported marijuana use in their diaries. Cotinine, a metabolite of nicotine, was
419 not detectable in the serum of nonsmokers and was significantly elevated in the serum of e-
420 cigarette users (127.99 ± 15.42) and smokers (170.16 ± 21.41) in comparison with nonsmokers
421 ($p < 0.0001$), as expected.

422

423 *Nasal Microbiome Characteristics*

424

425 The 4677 OTUs included in the dataset represented OTUs from 19 unique phyla and 225 unique
426 genera. The top four most abundant phyla by average relative abundance across all samples were
427 *Actinobacteria* (50.2%), *Firmicutes* (36%), *Proteobacteria* (12.0%), and *Bacteroidetes* (1.6%).

428 The top six most abundant genera by average relative abundance across all samples were
429 *Corynebacterium* (40.7%), *Staphylococcus* (19.9%), *Propionibacterium* (11.8%), *Alliococcus*
430 (8.5%), *Moraxella* (5.3%), and *Streptococcus* (4.2%). This microbial composition is similar to
431 previously reported studies of the nasal microbiome [61, 62]. These data are summarized in
432 **Figure 1**, where relative abundances by exposure group and sex are plotted for the most highly
433 abundant phyla and genera.

434

435

436

437

438 *Alpha Diversity*

439

440 To determine whether there are differences in alpha diversity between the nasal microbiomes of
441 smokers, nonsmokers, and e-cigarette users, we calculated alpha diversity indices (Observed,
442 Chao1, ACE, Shannon, Simpson, Fisher) using phyloseq [63]. We did not find any statistically
443 significant differences between the exposure groups for any measure of alpha diversity; however,
444 we did observe a non-significant trend of increased alpha diversity in smokers (**Figures 2A and**
445 **2B**). Because our group and others have previously observed sex differences in respiratory
446 mucosal immune responses [64, 65] we also tested whether alpha diversity was significantly
447 different between male and female subjects. We found that both the Shannon and Simpson
448 indices were significantly higher in males than females ($p = 0.021$ and $p = 0.0078$, respectively)
449 (**Figures 2C and 2D**). We then tested for the interaction between sex and exposure group and
450 found that sex was a significant source of observed variation ($p = 0.0286$ for Shannon; $p =$
451 0.0102 for Simpson), while exposure group was not. When the data were stratified by exposure
452 group, the only male-female comparison that remained significant was in the e-cigarette user
453 group ($p = 0.0361$ for Shannon; $p = 0.0124$ for Simpson) (**Figures 2E and 2F**). These results
454 suggest that sex is an important biological variable to consider in studies of the nasal
455 microbiome.

456

457 *Compositional Difference of the Nasal Microbiome by Sex*

458

459 Because we observed distinctions in alpha diversity between sexes, we next tested whether there
460 were significant compositional differences between the sexes and to identify specific genera

461 capable of explaining these dissimilarities. Given challenges presented by sparse, compositional
462 16S rRNA sequencing data combined with high-dimensionality (genera = 255) and small sample
463 size (n=62), we leveraged the SelEnergyPerm [32] method to identify a robust signature of nasal
464 microbiome taxa (among sparse noisy data) capable of explaining compositional differences
465 between sexes.

466

467 By applying this method, we discovered (beyond random noise) a subset of genera ($g = 6$)
468 capable of maximizing the energy distance between male and female samples ($p = 0.0123$,
469 **Figure S1A**). This microbial signature was comprised of four log ratios between *Rhodococcus*,
470 *Finegoldia*, *Sneathia*, *Abiotrophia*, *Tannerella*, and *Yaniella* genera (**Figure 3A**). Using the
471 identified log ratio signature, PERMANOVA analysis (pseudo-F = 16.586, $p = 0.0002$, **Figure**
472 **3B**) also confirmed the existence of differences in the nasal microbiome composition between
473 sex. Analysis of individual taxa log ratios between sexes demonstrated important nasal
474 microbiome compositional differences (**Figure 3C**). In female samples, *Yaniella* was more
475 abundant on average than *Rhodococcus* and *Tannerella*, while the reverse was true for males. In
476 male samples, *Abiotrophia* was more abundant on average than *Sneathia*, while the opposite was
477 true for females. Finally, in both males and females, *Finegoldia* was observed to be more
478 abundant than *Yaniella*, however, *Finegoldia* was significantly more enriched relative to *Yaniella*
479 in males compared to females.

480

481 Next, we analyzed the microbial signature as a whole using Partial Least Squares Discriminate
482 Analysis (PLS-DA) with a single component to predict sex. Using 20 repeats of 10-fold cross-
483 validation, the average area under the receiver operating characteristic curve (AUC) for

484 predicting sex given the reduced microbial signature was 0.862 (95% CI 0.842 – 0.883, **Figure**
485 **3D**). With strong cross-validated predictive performance, a final PLS-DA model was trained on
486 all samples (n=62). Scores from the single PLS-DA component indicated strong separation
487 between sexes (**Figure 3E**). The PLS-DA loading plot (**Figure 3F**), which shows how each log
488 ratio contributes to the final score, demonstrates key relationships between taxa log ratios.
489 Increased abundance of *Abiotrophia* and *Finegoldia* (in log ratios where they appear) were
490 characteristic of males, and increased abundance of *Yaniella* was associated with females.
491 Overall, these findings indicate there exists a compositionally distinct taxa subset that differs
492 strongly in the nasal microbiomes of males and females. Therefore, controlling for sex
493 differences present in the nasal microbiome is important in further analysis.

494

495 *Compositional Difference of the Nasal Microbiome by Exposure group*

496

497 We next examined whether there were distinct nasal microbiome compositions between
498 exposure groups (e-cigarette users: n = 24; smokers: n=19; nonsmokers: n=19; See Methods and
499 **Table 1**). Taking into account nasal microbiome sex differences and applying SelEnergyPerm,
500 we identified a subset of genera (g = 12) important for explaining key nasal microbiome
501 alterations between exposure groups (p = 0.032, **Figure S1B**). This microbial signature
502 comprised nine log ratios (edges) between 12 key genera (nodes) (**Figure 4A**). PERMANOVA
503 analysis (pseudo-F = 8.4889, p =0.0002, **Figure 4B**) confirmed differences in nasal microbiome
504 composition between exposure groups given the microbial signature of 9 log ratios.

505

506 Individual analyses of log ratios elucidated specific compositional differences between exposure
507 groups (**Figure 4C**). In e-cigarette users, *Lactobacillus* taxa were significantly more abundant
508 relative to *Bacillus* taxa, while in smokers and nonsmokers, these taxa presented in similar
509 proportions, suggesting an enrichment of *Lactobacillus* among e-cigarette users. E-cigarette
510 users' nasal microbiomes also contained significantly more *Staphylococcus* relative to *Bacillus*
511 than what was observed in nasal microbiomes of both smokers ($q = 0.0097$) and nonsmokers ($q =$
512 0.0031). In smokers, *Maccrococcus* genera were significantly more abundant on average relative to
513 *Hymenobacter*, *Mycobacterium*, *Varibaculum*, and *Rhodococcus*, suggesting that smoking may
514 enrich *Macroccoccus* taxa populations in the nasal passage. Additionally, smoker nasal
515 microbiomes contained more *Hymenobacter* relative to *Moryella*, whereas the opposite was true
516 for nonsmokers, both in contrast to e-cigarette users, which maintained on average equal
517 amounts of both genera. In nonsmokers, *Lautropia* taxa were significantly more abundant
518 relative to *Bulleidia*, but this was not observed in smokers and e-cigarette users.

519

520 To understand how taxa log ratios work together to discriminate between exposure groups, PLS-
521 DA was used with 20 repeats of 10-fold cross-validation (**Figure 4D**). The estimated multi-
522 classification AUC was 0.851 (95% CI 0.835 – 0.866) suggesting excellent exposure group
523 discrimination. Pairwise examination of exposure group classifications shows strong differences
524 between the nasal microbiomes of nonsmokers/e-cigarette users (AUC = 0.895: 95% CI 0.874 –
525 0.915) and smokers/e-cigarette users (AUC = 0.893: 95% CI 0.873 – 0.913), with weaker yet
526 distinct differences between smokers/nonsmokers (AUC = 0.803: 95% CI 0.773 – 0.833)
527 (**Figure 4D**). The relative importance of taxa log ratios for discriminating between exposure
528 groups was computed using a final PLS-DA model fit using all samples ($n=62$). The log ratio

529 between *Macroccoccus* relative to *Hymenobacter* was found to be most important for classifying
530 samples as smoker (least important for e-cigarette user classification), and the log ratio between
531 *Bacillus* taxa relative to taxa from the *Micrococcaceae* family was most important for samples to
532 be classified as e-cigarette users (least important to be classified as smokers). (Figure 4E).
533 Interestingly, inspection of relative log ratio importance data failed to uncover log ratios
534 disproportionately important for nonsmokers. This observation suggests smoking and e-cigarette
535 use recognizably alter the nasal microbiome in otherwise healthy adults. Overall, analysis of the
536 taxa log ratios signature suggests alterations in *Macroccoccus* and *Bacillus* genera are important
537 for distinguishing between these exposure groups.

538

539 *Differences in NLF mediator Expression Patterns Between Exposure groups*

540

541 Because smoking and e-cigarette use were associated with distinct changes in the nasal
542 microbiome, we next explored if there was altered expression of innate immune response
543 mediators in the exposure groups. Accounting for differences in absolute concentration (Figure
544 S3A) and subsequently applying differential compositional variation scoring [32] (See Methods,
545 Figure S3B), we identified four log ratios among NLF mediators that showed strong intergroup
546 variability (Figure S3C). These ratios comprised the following NLF mediators: IL-8, DEFB4A-
547 2, neutrophil elastase, IgA, and lactoferrin. Kruskal-Wallis one-way testing (Figure S3D) of
548 each log ratio suggest there exist intergroup differences in NLF mediator expression formed
549 between the concentrations of neutrophil elastase relative to IL-8 ($H = 6.4417$; $p = 0.0399$; $q =$
550 0.0798) and lactoferrin relative to IL-8 ($H = 8.2080$; $p = 0.0165$; $FDR = 0.0660$). There were no
551 significant differences between exposure groups among log ratios formed by IgA relative to IL-8

552 or DEFB4A-2 relative to neutrophil elastase. However, multivariate analysis with
553 PERMANOVA (pseudo-F = 3.7678, p = 0.0030) using the four key log ratios confirmed there
554 were differences in NLF mediator expression patterns between exposure groups when considered
555 together. To better understand which groups were different, we applied PLS-DA. Training a
556 PLS-DA model with the NLF mediator expression patterns revealed the strongest between-
557 subject-group discrimination to be among Smokers and Nonsmokers (AUROC = 0.8230, 95%CI
558 0.7920-0.8530, **Figure S3E**). Notably, e-cigarette users' NLF mediators were weakly
559 distinguishable from nonsmokers (AUROC = 0.6720, 95%CI 0.6350-0.7100, **Figure S3E**) but
560 more discernible from smokers (AUROC = 0.7480, 95%CI 0.7130-0.7820, **Figure S3E**).
561 Together, these results suggest that the expression of NLF mediators in smokers was distinct
562 from that of e-cigarette users and healthy adults.

563

564 *Integration of NLF mediators and nasal microbiome composition improves exposure group*
565 *discrimination*

566

567 Finally, we aimed to understand if alterations in NLF mediator expression are associated with
568 nasal microbiome dysbiosis resulting from smoking or e-cigarette use. To this end, we first
569 estimated the discriminatory AUROC of a 2-component PLS-DA model fit on log ratios from
570 NLF mediators (**Figures S2C - S3**), nasal microbiome (**Figures 4A – S4A**), or both nasal
571 microbiome and NLF mediators (**Figure 5A**). When compared to individual signatures,
572 improved discriminatory AUROC (**Figure 5B**) was observed when PLS-DA models were fit
573 using the combined nasal microbiome and NLF mediator signatures. Therefore, with established

574 synergy between mediator expression and nasal microbiome composition in discriminating
575 between exposure groups, we next examined if correlations were present between the two.

576

577 *Association between altered NLF mediator expression and nasal microbiome dysbiosis*

578

579 Using the first PLS-DA component of the nasal microbiome signature, we found significant
580 correlations with NLF mediator expression, showing an association between the nasal
581 microbiome composition and NLF mediator expression (**Figure 5C**). Examination of the
582 location of samples by exposure group projected along the first PLS-DA component show
583 important projective distinctions between smokers (on average negative projections) and both e-
584 cigarette users and nonsmokers (on average positive projections) (**Figure S4B**). Given this, these
585 correlations suggest nasal microbiome dysbiosis caused by cigarette smoke exposure is
586 associated with increased expression of IL-8 relative to neutrophil elastase, Total IgA, and
587 lactoferrin (**Figure 5C**). Moreover, the loadings along the first PLS-DA component (**Figure**
588 **S4C**) show log ratios with higher abundance of *Maccroccous* as being the most important
589 contributor to negative projections. Combined, these data propound an important link between
590 dysbiosis in *Macroccocus* communities within the nasal microbiome and NLF IL-8 expression.

591

592 *Microbial functional and mediator expression differences between exposure groups*

593

594 Correlation analysis of the combined NLF mediator expression and nasal microbiome signature
595 reveal distinct correlation patterns within exposure groups suggesting distinct functional
596 differences (**Figures 5D**). Most notably, a significant negative correlation between log ratios

597 formed by *Hymenobacter/Moryella* and *Macrocooccus/Hymenobacter* was observed only in the
598 nonsmoker group. This negative correlation highlights a possible role of *Hymenobacter*, in that it
599 appears to be important for maintaining a healthy balance of *Maccroocous* and *Moryella*. In the
600 e-cigarette and smoking groups, we observed a significant positive correlation between the log
601 ratios formed by IgA/IL-8 and Lactoferrin/IL-8. Analysis of this correlation pattern reveals that
602 increased expression of IL-8 in these groups may come at the expense of decreased expression of
603 IgA and lactoferrin or vice versa. We also observed a significant negative correlation between
604 the log ratios formed by Neutrophil Elastase/IL-8 and DEFB4A-2/Neutrophil Elastase in the e-
605 cigarette and smoking groups. These strong negative correlations show that increased expression
606 of IL-8 and DEFB4A-2 subsequently results in decreased expression of neutrophil elastase. The
607 final significant correlation pattern observed was in smokers only and consisted of four
608 positively correlated log ratios formed by *Macrocooccus* relative to *Hymenobacter*,
609 *Mycobacterium*, *Varibaculum*, and *Rhodococcus* (Figure 5D). Relatively interpreting these
610 correlations between log ratios suggests that as *Macrocooccus* becomes more abundant (among
611 these ratios) the abundance of *Hymenobacter*, *Mycobacterium*, *Varibaculum*, and *Rhodococcus*
612 decreases. This suggests that cigarette smoke exposure may produce favorable colonization
613 conditions for *Maccroccous* genera which subsequently reduces the abundance of
614 *Hymenobacter*, *Mycobacterium*, *Varibaculum*, and *Rhodococcus*.

615

616 From these analyses, our results demonstrate there exists a strong association between altered
617 NLF mediator expression and nasal microbiome dysbiosis. Our findings indicate nasal
618 microbiome dysbiosis from smoking results in the simultaneous increase in IL-8 expression and
619 *Maccroccous* abundance. Additionally, variations in the correlation networks among e-cigarette

620 users and smokers, while similar, were distinct from nonsmokers, suggesting functional
621 differences at the microbial and mediator levels between exposure groups.

622

623 **Discussion**

624

625 Despite the growing body of research showing that e-cigarette use can disrupt the
626 respiratory immune system, no studies to date have assessed the effects of e-cigarettes on the
627 respiratory microbiome and host-microbiota interactions. In this study, after adjusting for sex
628 differences, we found that e-cigarette users, smokers, and nonsmokers have unique nasal
629 microbiomes, with differences driven by the relationships between a subset of key taxa. We also
630 found a subset of immune mediators that had distinct relationships between each other in the
631 different exposure groups. Importantly, we found a link between nasal microbiome dysbiosis and
632 soluble immune mediator networks.

633 A fundamental feature of our study is that we detected microbial signatures from the
634 nasal microbiome that explained differences between sex and exposure groups using the novel
635 SelEnergyPerm computational method. This method directly accounts for the sparse, high-
636 dimensional and compositional nature of the 16S relative abundance data. Additionally,
637 SelEnergyPerm identifies subsets of robust log ratios between taxa, as opposed to analyzing taxa
638 relative abundance alone, yielding higher statistical power in the sparse association setting with
639 low-sample-size compositional data [32]. Most importantly, traditional statistical techniques
640 such as PERMANOVA, ANOSIM, and ANCOM alone were unable to detect these sparse
641 associations within the high-dimensional nasal microbiome feature space. Further, our
642 parsimonious yet statistically significant signatures were then integrated with NLF mediators

643 where we were then able to uncover novel interactions between a taxa subset within the nasal
644 microbiome and the NLF mediators in response to exposure to cigarette or e-cigarette aerosol.

645 We observed that there were relationships between a subset of taxa that were important in
646 separating the microbial communities of smokers, nonsmokers, and e-cigarette users (**Figure 4**).
647 Only a few studies have previously compared the nasal microbiome of smokers and nonsmokers
648 [23, 66]. Charlson et al. found specific bacteria genera that were differentially abundant in
649 smokers and that some genera belonging to the phylum *Firmicutes* were important in
650 distinguishing smokers from nonsmokers [23]. Other studies did not find any significant
651 differences in diversity measures or relative taxa abundance between smokers and nonsmokers
652 [66]. In our study, which focused on the composition of the nasal microbiome and ratios between
653 taxa rather than relative abundance of individual taxa, we found that alterations in *Macrococcus*
654 and *Bacillus* genera are important for distinguishing between exposure groups. Our data also
655 suggest an enrichment of *Lactobacillus* and *Staphylococcus* relative to *Bacillus* in e-cigarette
656 users and enrichment of *Macrococcus* relative to *Hymenobacter*, *Mycobacterium*, *Varibaculum*,
657 and *Rhodococcus* in smokers. A shift from *Lactobacillus* to *Bacillus* in the lung microbiome has
658 been previously demonstrated in response to influenza A infection and increases in anaerobic
659 bacteria, such as *Lactobacillus*, have been associated with chronic rhinosinusitis [61].
660 Furthermore, *Bacillus* have been shown to produce antimicrobials against *S. aureus* [67],
661 indicating that the patterns we have observed may be directly linked to specific interactions
662 between taxa. An increase in *Staphylococcus* relative to *Bacillus* in e-cigarette users is also
663 notable due to the role of species such as *Staphylococcus aureus*, which is carried normally by
664 about 30% of people and is also considered to be a potential pathogen of the skin and mucosal
665 surfaces [68, 69]. Our data provide evidence that e-cigarette and smoker nasal microbiomes are

666 distinctly shifted from nonsmokers. Importantly, we also observed that different subsets of taxa
667 were important in separating e-cigarette users and smokers, rather than effects on a continuum
668 from nonsmokers to e-cigarette users to smokers, highlighting the concept that the effects of e-
669 cigarettes are likely unique from those of smokers, even though they are commonly directly
670 compared.

671 We also measured concentrations of mediators of host-microbiota interactions in nasal
672 lavage fluid to determine whether the changes in the nasal microbiome in different exposure
673 groups are potentially caused by direct effects on the microbiome, mediated by changes in the
674 host immune system, or both. Our data indicate that the expression of immune mediators in nasal
675 lavage fluid samples differed among exposure groups and was driven by shifts in neutrophil
676 elastase and lactoferrin relative to IL-8. Neutrophil elastase and IL-8 are associated with
677 inflammation and neutrophil recruitment, while lactoferrin is an antimicrobial protein primarily
678 produced by epithelial cells and has a wide array of functions, including antioxidant and
679 immune-modulating properties [70]. Our results suggest that e-cigarette users and smokers may
680 have altered immune mediator milieu, indicating a shift away from immune homeostasis and
681 towards increased inflammation and neutrophil recruitment. This shift could be partially driving
682 observed differences in the nasal microbiome.

683 Our data indicate that both e-cigarette users and smokers have altered nasal microbial
684 communities and relationships between markers of innate immune response, which could imply
685 that they are at increased susceptibility to respiratory infections and/or that they exist in a state of
686 inflammation and altered immune response. We also uncovered interactions of key immune
687 mediators with the host and microbiota, such as IL-8, neutrophil elastase, and lactoferrin, that are
688 also disrupted by e-cigarette and cigarette use. The microbial shifts we observed in association

689 with e-cigarette and cigarette use could be driven by changes in the microenvironment, such as
690 temperature, pH, free radical formation, and availability of metabolic substrates (e.g. sugars) that
691 could then alter the fitness of different bacteria in the nasal microbial community. The shifts we
692 observed could also be mediated through direct effects on respiratory host defense function,
693 inflammation, and/or specific microbes. Multiple processes are likely at play, but our novel
694 findings on the effects of e-cigarettes on the nasal microbiome add to the growing body of
695 literature demonstrating that e-cigarettes are not without health effects and that they should be
696 more thoroughly investigated for inhalational toxicity.

697 Because sex differences in the human immune system and its response to respiratory
698 disease and toxicant exposure have been observed previously [64, 71], we also investigated
699 whether there were sex differences in the nasal microbiomes of our subjects. We observed that
700 the relationships between six genera were important in separating the nasal microbiomes of
701 males and females (Figure 4A). Increased abundance of *Abiotrophia* and *Finegoldia* (in log
702 ratios where they appear) were characteristic of males, and increased abundance of *Yaniella* was
703 associated with Females. Many of these genera have been detected in previous studies of skin,
704 oral, and/or respiratory microbiomes [23, 61, 72-76], but detailed information on the functions of
705 these bacteria as part of the microbial community, as well as their impact on host health, are not
706 available for all taxa. Although some of these genera, such as *Abiotrophia* and *Finegoldia* have
707 been associated with disease- and exposure-driven alterations in the respiratory microbiome [23,
708 61, 72, 73], we hypothesize that the observed sex difference is neither good nor bad; rather, it is
709 reflective of a different baseline composition in males and females or altered microenvironments
710 in males and females due to differences in toxicant metabolism rates or mechanisms of immune
711 regulation [77, 78]. In other body sites, such as the gut, sex differences have been detected and

712 have been attributed to a variety of factors, including sex hormone levels, pharmaceutical use,
713 and diet [79, 80]. In mice, sex-related differences in gut microbiota were shown to impact
714 pulmonary responses to ozone [65]. However, few studies have explored sex differences in the
715 respiratory microbiome [81]. In the studies that have analyzed data by sex, detection of sex
716 differences is not consistent between studies and is typically not explored in-depth [62, 68, 82].
717 Importantly for the data presented here, compositional differences in the nasal microbiomes of e-
718 cigarette users, smokers, and nonsmokers were not apparent until sex was properly adjusted for,
719 further underscoring the importance of considering sex as a biological variable which
720 significantly modifies exposure effects and can substantially affect data interpretation.

721 Though our study reveals important community shifts in nasal microbiota and immune
722 mediators associated with e-cigarette and cigarette use as well as with sex, there are limitations
723 to our study. Our novel analysis approach, while properly accounting for the compositional
724 nature of the data, limits us in comparing our work to previous studies, which have been more
725 focused on specific taxa rather than ratios across the microbial community as a whole. As with
726 any study of human subjects, there is also inherent inter-subject variability that can interfere with
727 detection of differences between groups. In our e-cigarette user group, there was considerable
728 variability in factors that could impact the exposure subjects are receiving, including e-liquid
729 flavor, device, nicotine content, and frequency of use. The e-cigarette user group also includes
730 previous smokers and some marijuana use was reported in both smoker and e-cigarette user
731 questionnaires. These factors were included in our analysis and did not show a significant impact
732 on our overall findings due to the nature of the computational models we used. In future studies,
733 larger cohort sizes coupled with more extensive questionnaires could improve the ability to
734 detect which, if any, of these factors may be driving changes in microbiota composition and

735 would also increase power to detect overall changes and shifts in the nasal microbiomes of such
736 subjects given the compositional and sparse nature of 16S sequencing data.

737 As a whole, our results support and expand on the previously published notion that
738 exposure to inhaled toxicants, including tobacco products, can influence the respiratory
739 microbiome [23, 83, 84]. The novel, robust computational approach in terms of pairwise log
740 ratios that we applied allowed us to uncover both exposure- and sex-dependent effects on nasal
741 mucosal host defense responses using straightforward, non-invasive sampling of the upper
742 respiratory tract of human subjects. Importantly, we were able to integrate 16S sequencing data
743 with expression of soluble immune mediators to understand interactions between the nasal
744 microbiome and host milieu by appropriately handling the sparse, compositional data generated
745 by 16S sequencing, accounting for inter-individual variability between subjects' mediator levels,
746 and selecting for features that were most important for separating classes, resulting in
747 interpretable, biologically meaningful results. Conventional analysis pipelines would have
748 limited our ability to integrate these two types of data and detect the exposure and sex-dependent
749 effects we observed, highlighting the importance of applying innovative computational methods
750 to address specific research questions and integrating multiple factors in understanding
751 biological outcomes of exposure and disease.

752

753 **Conclusions**

754

755 Using a novel computational approach, we detected respiratory dysbiosis associated with
756 both e-cigarette use and cigarette smoking, and we demonstrated interactions between immune
757 mediators and microbial dysbiosis in the nasal mucosa. This is the first study to report on the

758 effects of e-cigarette use on the respiratory microbiome and host-microbiota interactions, and the
759 first study to thoroughly investigate and account for biological-sex-driven differences in the
760 human nasal microbiome. Overall, our study introduces a novel computational approach that is
761 well-suited to detect biologically meaningful differences in clinical studies of moderate sample
762 size with multiple interconnected datasets. These data would have been challenging to integrate
763 appropriately using conventional microbiome analysis approaches, and our study provides an
764 example for how similar studies can be analyzed in the future while also revealing important
765 biological differences in the nasal mucosa that are associated with e-cigarette use, cigarette
766 smoking, and sex.

767

768 **Declarations**

769

770 *Ethics approval and consent to participate.* All human subjects research was performed in
771 accordance with the Declaration of Helsinki and was approved by the University of North
772 Carolina at Chapel Hill Institutional Review Board (UNC IRB #13-3454).

773

774 *Consent for publication:* Not applicable.

775

776 *Availability of data and material:* Raw sequencing data is available under the SRA BioProject
777 accession number PRJNA746950. Processed OTU and NLF tables by exposure group and sex
778 have been deposited in the github repository:

779 https://github.com/andrew84830813/nasalMicrobiome_EcigSmoking/Data/

780

781 All nasal microbiome analyses were done using version 4.0.0 of the R statistical programming
782 language. All input data, R script, and functions used in the analysis presented here can be
783 retrieved from the github repository:

784 https://github.com/andrew84830813/nasalMicrobiome_EcigSmoking.git

785

786 *Competing Interests Statement:* The authors report no competing interests.

787

788 *Funding:* This research was funded by the National Institutes of Health

789 (NIH) Grant Nos. R01 HL139369, T32 ES007126, P50 HL120100, and F31 HL154758, by an

790 HHMI Gilliam Award (GT11504), and by a JSMF Complex Systems Scholar Award

791 (#220020315). The content is solely the responsibility of the authors and does not necessarily

792 represent the official views of any agency funding this research.

793

794 *Authors' Contributions:* I.J. and E.H. conceived the study and were in charge of overall direction

795 and planning. M.E.R., C.R., and I.J. contributed to clinical research operations, including the

796 collection and processing of samples and subject demographic data. B.Z. and M.W. performed

797 metagenomic sequencing, quality control, and analysis through OTU assignment. E.H.

798 performed experiments to measure proteins in nasal lavage fluid. A.H. led the remaining data

799 analysis with help from E.H. and feedback from P.J.M. and I.J.. E.H. and A.H. took the lead in

800 writing the manuscript. All authors provided feedback on and helped shape the final manuscript.

801

802

803

804

805

806

807 **Table 1.** Subject demographics. Reported values are mean \pm standard error. Groups were
 808 compared using the Steel Dwass method for non-parametric multiple comparisons. AA = African
 809 American. # $p < 0.05$ in comparison with nonsmokers and smokers. **** $p < 0.0001$ in
 810 comparison with nonsmokers.

	Nonsmokers	E-Cigarette Users	Smokers
n	20	28	19
Sex (Male/Female)	8/12	19/9	10/9
Race (White/AA/Asian/Other)	16/1/2/1	18/4/5/1	10/8/0/1
Age	30.75 \pm 1.32	26.39 \pm 1.44 [#]	31.89 \pm 1.91
BMI	27.11 \pm 1.31	30.07 \pm 1.51	27.65 \pm 1.43
Cigarettes/Day	0 \pm 0	0.14 \pm 0.07	12.68 \pm 0.96
mL E-Liquid/Day	0 \pm 0	3.60 \pm 0.70	0.015 \pm 0.015
E-Cigarette Puffs/Day	0 \pm 0	53.90 \pm 16.54	0.466 \pm 0.414
E-Liquid Nicotine (mg/mL)	0 \pm 0	19.43 \pm 4.92	0.158 \pm 0.158
Former Cigarette Smoker (Yes/No)	0/20	22/6	19/0
Marijuana Use (Yes/No)	0/20	4/24	4/15
Serum Cotinine (ng/mL)	0 \pm 0	127.99 \pm 15.42****	170.16 \pm 21.41****

811
 812
 813
 814
 815




Figure 1. Average relative abundances of the top 4 phyla (A-C) and top 10 genera (D-E) plotted by exposure group (A, D), sex (B, E), and sex within exposure groups (C, F). NS = nonsmoker, EC = e-cigarette user, SM = smoker, M = male, F = female.

816
 817
 818




Figure 2. Shannon and Simpson indices of alpha diversity are significantly different between sexes, and this difference is most pronounced in e-cigarette users. The Shannon and Simpson indices for alpha diversity were calculated and plotted by exposure group (A, B), sex (C, D), and sex within exposure groups (E, F). NS = nonsmoker, EC = e-cigarette user, SM = smoker. Data are presented as mean \pm standard error. * $p < 0.05$, ** $p < 0.01$ by t-test (C), Kruskal-Wallis test (D), or two-way ANOVA with Fisher's LSD (E, F).

820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835




Figure 3 | Nasal microbiome differences between sexes (Males: n=35; Females: n=27). (A) Network representation of SelEnergyPerm (p=0.0123) derived genus aggregated taxa log ratio signature of nasal microbiome differences between sexes (Node = genera; edge = log ratio between taxa, Edge-weight = Kruskal Wallis H-statistic between sexes, Size/Color = node strength). (B) Principal coordinate analysis plot of nasal microbiome log ratio signature between sex explaining 82.37% of the total variation. (C) Univariate analysis of log ratio signature showing average depletion or enrichment of specific taxa log ratios between sexes. Error bars reflect 95% confidence intervals of the mean log-ratio value for males and females. (D) Receiver operating characteristics (ROC) curve displaying the area under the curve (AUC) predictive performance (20x10-fold cross-validation) of 1-component partial least squares discriminant analysis (PLS-DA) models trained on nasal microbiome signature between sexes. (E) PLS-DA scores plot of single discriminating component between sexes. Final PLS-DA model fit using all samples (n=62). (F) PLS-DA loadings plot showing contributions of each log ratio to final scores.

836
837
838
839
840
841
842




Figure 4 | Nasal microbiome differences between exposure groups (Ecig-users: n=24; Nonsmokers: n=19; and Smokers: n=19) adjusted for sex. (A) Network representation of SelEnergyPerm ($p=0.032$) derived genus aggregated taxa log ratio signature of nasal microbiome differences between exposure groups (Node = genera; edge = log ratio between taxa, Edge-weight = Kruskal Wallis H-statistic between sex, Size/Color = node strength). (B) Principal coordinate analysis plot of nasal microbiome log ratio signature between exposure groups explaining 62.63% of the total variation. (C) Univariate analysis of log ratio signature showing average depletion or enrichment of specific taxa log ratios between exposure groups. Error bars reflect 95% confidence intervals of the mean log-ratio value for each exposure group. (D) ROC curve displaying the multi-classification AUC for predicting exposure group (20x10-fold cross-validation) of 2-component PLS-DA models trained on nasal microbiome signature between exposure groups. (E) Relative importance of log ratios for distinguishing between exposure groups in PLS-DA model trained on all samples (n=62).

843
 844
 845
 846
 847
 848
 849
 850




Figure 5 | Integrating data uncovers association between NLF mediators and nasal microbiome along with identifying distinct correlation patterns between exposure groups (Ecig-users: $n=23$; Nonsmokers: $n=19$; and Smokers: $n=19$). (A) PLS-DA biplot of integrated NLF mediators and nasal microbiome (B) Box and whisker's plot comparing area under the receiver operating characteristic curve performance of 2-component PLS-DA model (50x10-fold cross-validation) using each data type alone or integrated. (C) Scatter plot showing correlations between log ratios formed between concentrations ($\mu\text{g}/\text{mL}$) of Lactoferrin, Neutrophil Elastase relative to IL-8 and the first PLS-DA component of the nasal microbiome. (D) Correlation heatmap showing Pearson's correlation coefficients (PCC) between and within the microbiome and protein log ratio signatures. (* indicates within group $q \leq 0.10$)

851
852
853
854
855
856
857
858
859
860
861

862 **References**

- 863 1. Wang T, Asman K, Gentzke A, al. e. Tobacco Product Use Among Adults — United States,
864 2017. *MMWR Morb Mortal Wkly Rep.* 2017;67(45):1225–32; doi:
865 <http://dx.doi.org/10.15585/mmwr.mm6744a2>
- 866 2. Leventhal AM, Miech R, Barrington-Trimis J, Johnston LD, O’Malley PM, Patrick ME.
867 Flavors of e-Cigarettes Used by Youths in the United States. *Jama.* 2019; doi:
868 10.1001/jama.2019.17968.
- 869 3. Wang TW, Neff LJ, Park-Lee E, Ren C, Cullen KA, King BA. E-cigarette Use Among Middle
870 and High School Students - United States, 2020. *MMWR Morb Mortal Wkly Rep.*
871 2020;69(37):1310-2; doi: 10.15585/mmwr.mm6937e1.
- 872 4. Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, et al. e-Cigarette Use
873 Among Youth in the United States, 2019. *Jama.* 2019; doi: 10.1001/jama.2019.18387.
- 874 5. Kiernan E, Click ES, Melstrom P, Evans ME, Layer MR, Weissman DN, et al. A Brief
875 Overview of the National Outbreak of e-Cigarette, or Vaping, Product Use-Associated
876 Lung Injury and the Primary Causes. *Chest.* 2021;159(1):426-31; doi:
877 10.1016/j.chest.2020.07.068.
- 878 6. McAlinden KD, Eapen MS, Lu W, Chia C, Haug G, Sohal SS. COVID-19 and vaping: risk for
879 increased susceptibility to SARS-CoV-2 infection? *Eur Respir J.* 2020;56(1); doi:
880 10.1183/13993003.01645-2020.
- 881 7. Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, et al. E-
882 cigarette use results in suppression of immune and inflammatory-response genes in
883 nasal epithelial cells similar to cigarette smoke. *Am J Physiol Lung Cell Mol Physiol.*
884 2016;311(1):L135-44; doi: 10.1152/ajplung.00170.2016.
- 885 8. Reidel B, Radicioni G, Clapp PW, Ford AA, Abdelwahab S, Rebuli ME, et al. E-Cigarette
886 Use Causes a Unique Innate Immune Response in the Lung, Involving Increased
887 Neutrophilic Activation and Altered Mucin Secretion. *Am J Respir Crit Care Med.*
888 2018;197(4):492-501; doi: 10.1164/rccm.201708-1590OC.
- 889 9. Clapp PW, Pawlak EA, Lackey JT, Keating JE, Reeber SL, Glish GL, et al. Flavored e-
890 cigarette liquids and cinnamaldehyde impair respiratory innate immune cell function.
891 *Am J Physiol Lung Cell Mol Physiol.* 2017;313(2):L278-L92; doi:
892 10.1152/ajplung.00452.2016.
- 893 10. Clapp PW, Lavrich KS, van Heusden CA, Lazarowski ER, Carson JL, Jaspers I.
894 Cinnamaldehyde in flavored e-cigarette liquids temporarily suppresses bronchial
895 epithelial cell ciliary motility by dysregulation of mitochondrial function. *Am J Physiol*
896 *Lung Cell Mol Physiol.* 2019;316(3):L470-l86; doi: 10.1152/ajplung.00304.2018.
- 897 11. Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, et al. Electronic cigarettes
898 disrupt lung lipid homeostasis and innate immunity independent of nicotine. *J Clin*
899 *Invest.* 2019;129(10):4290-304; doi: 10.1172/jci128531.
- 900 12. Ghosh A, Coakley RD, Ghio AJ, Muhlebach MS, Esther CR, Jr., Alexis NE, et al. Chronic E-
901 Cigarette Use Increases Neutrophil Elastase and Matrix Metalloprotease Levels in the
902 Lung. *Am J Respir Crit Care Med.* 2019; doi: 10.1164/rccm.201903-0615OC.
- 903 13. Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, et al. Exposure to
904 electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse
905 model. *PLoS One.* 2015;10(2):e0116861; doi: 10.1371/journal.pone.0116861.

- 906 14. Gerloff J, Sundar IK, Freter R, Sekera ER, Friedman AE, Robinson R, et al. Inflammatory
907 Response and Barrier Dysfunction by Different e-Cigarette Flavoring Chemicals
908 Identified by Gas Chromatography-Mass Spectrometry in e-Liquids and e-Vapors on
909 Human Lung Epithelial Cells and Fibroblasts. *Appl In Vitro Toxicol*. 2017;3(1):28-40; doi:
910 10.1089/aivt.2016.0030.
- 911 15. Muthumalage T, Prinz M, Ansah KO, Gerloff J, Sundar IK, Rahman I. Inflammatory and
912 Oxidative Responses Induced by Exposure to Commonly Used e-Cigarette Flavoring
913 Chemicals and Flavored e-Liquids without Nicotine. *Front Physiol*. 2017;8:1130; doi:
914 10.3389/fphys.2017.01130.
- 915 16. Behar RZ, Luo W, McWhirter KJ, Pankow JF, Talbot P. Analytical and toxicological
916 evaluation of flavor chemicals in electronic cigarette refill fluids. *Sci Rep*.
917 2018;8(1):8288; doi: 10.1038/s41598-018-25575-6.
- 918 17. Clapp PW, Lavrich KS, van Heusden C, Lazarowski ER, Carson JL, Jaspers I.
919 Cinnamaldehyde in Flavored E-Cigarette Liquids Temporarily Suppresses Bronchial
920 Epithelial Cell Ciliary Motility by Dysregulation of Mitochondrial Function. *Am J Physiol*
921 *Lung Cell Mol Physiol*. 2019; doi: 10.1152/ajplung.00304.2018.
- 922 18. Hickman E, Herrera CA, Jaspers I. Common E-Cigarette Flavoring Chemicals Impair
923 Neutrophil Phagocytosis and Oxidative Burst. *Chemical research in toxicology*.
924 2019;32(6):982-5; doi: 10.1021/acs.chemrestox.9b00171.
- 925 19. Hwang JH, Lyes M, Sladewski K, Enany S, McEachern E, Mathew DP, et al. Electronic
926 cigarette inhalation alters innate immunity and airway cytokines while increasing the
927 virulence of colonizing bacteria. *J Mol Med (Berl)*. 2016;94(6):667-79; doi:
928 10.1007/s00109-016-1378-3.
- 929 20. Miyashita L, Suri R, Dearing E, Mudway I, Dove RE, Neill DR, et al. E-cigarette vapour
930 enhances pneumococcal adherence to airway epithelial cells. *Eur Respir J*. 2018;51(2);
931 doi: 10.1183/13993003.01592-2017.
- 932 21. Man WH, de Steenhuijsen Pijters WA, Bogaert D. The microbiota of the respiratory tract:
933 gatekeeper to respiratory health. *Nat Rev Microbiol*. 2017;15(5):259-70; doi:
934 10.1038/nrmicro.2017.14.
- 935 22. Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung
936 diseases. *Eur Respir J*. 2017;50(3); doi: 10.1183/13993003.02467-2016.
- 937 23. Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, et al. Disordered microbial
938 communities in the upper respiratory tract of cigarette smokers. *PLoS One*.
939 2010;5(12):e15216; doi: 10.1371/journal.pone.0015216.
- 940 24. Ramakrishnan VR, Hauser LJ, Frank DN. The sinonasal bacterial microbiome in health
941 and disease. *Curr Opin Otolaryngol Head Neck Surg*. 2016;24(1):20-5; doi:
942 10.1097/moo.0000000000000221.
- 943 25. Grønseth R, Drengenes C, Wiker HG, Tangedal S, Xue Y, Husebø GR, et al. Protected
944 sampling is preferable in bronchoscopic studies of the airway microbiome. *ERJ Open*
945 *Research*. 2017;3(3):00019-2017; doi: 10.1183/23120541.00019-2017.
- 946 26. Di Stadio A, Costantini C, Renga G, Pariano M, Ricci G, Romani L. The Microbiota/Host
947 Immune System Interaction in the Nose to Protect from COVID-19. *Life (Basel)*.
948 2020;10(12):345; doi: 10.3390/life10120345.

- 949 27. Rosas-Salazar C, Kimura KS, Shilts MH, Strickland BA, Freeman MH, Wessinger BC, et al.
950 SARS-CoV-2 Infection and Viral Load are Associated with the Upper Respiratory Tract
951 Microbiome. *J Allergy Clin Immunol*. 2021; doi: 10.1016/j.jaci.2021.02.001.
- 952 28. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current
953 understanding of the human microbiome. *Nature Medicine*. 2018;24(4):392-400; doi:
954 10.1038/nm.4517.
- 955 29. Li H. Statistical and Computational Methods in Microbiome and Metagenomics. In:
956 Handbook of Statistical Genomics. 2019. p. 977-550.
- 957 30. Jiang D, Armour CR, Hu C, Mei M, Tian C, Sharpton TJ, et al. Microbiome Multi-Omics
958 Network Analysis: Statistical Considerations, Limitations, and Opportunities. *Frontiers in*
959 *Genetics*. 2019;10(995); doi: 10.3389/fgene.2019.00995.
- 960 31. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets Are
961 Compositional: And This Is Not Optional. *Frontiers in Microbiology*. 2017;8; doi:
962 10.3389/fmicb.2017.02224.
- 963 32. Hinton AL, Mucha PJ. A simultaneous feature selection and compositional association
964 test for detecting sparse associations in high-dimensional metagenomic data (PREPRINT
965 - Version 1). PREPRINT Version 1 available at Research Square. 2021; doi:
966 <https://doi.org/10.21203/rs.3.rs-703177/v1>.
- 967 33. Rebuli ME, Speen AM, Clapp PW, Jaspers I. Novel applications for a noninvasive
968 sampling method of the nasal mucosa. *Am J Physiol Lung Cell Mol Physiol*.
969 2017;312(2):L288-I96; doi: 10.1152/ajplung.00476.2016.
- 970 34. Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, et al. Initial
971 acquisition and succession of the cystic fibrosis lung microbiome is associated with
972 disease progression in infants and preschool children. *PLoS Pathog*.
973 2018;14(1):e1006798; doi: 10.1371/journal.ppat.1006798.
- 974 35. Horvath KM, Herbst M, Zhou H, Zhang H, Noah TL, Jaspers I. Nasal lavage natural killer
975 cell function is suppressed in smokers after live attenuated influenza virus. *Respir Res*.
976 2011;12:102; doi: 10.1186/1465-9921-12-102.
- 977 36. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical
978 identification and removal of contaminant sequences in marker-gene and
979 metagenomics data. *Microbiome*. 2018;6(1):226; doi: 10.1186/s40168-018-0605-2.
- 980 37. Drengenes C, Wiker HG, Kalanathan T, Nordeide E, Eagan TML, Nielsen R. Laboratory
981 contamination in airway microbiome studies. *BMC Microbiol*. 2019;19(1):187; doi:
982 10.1186/s12866-019-1560-1.
- 983 38. Quinn TP, Erb I, Gloor G, Notredame C, Richardson MF, Crowley TM. A field guide for the
984 compositional analysis of any-omics data. *GigaScience*. 2019;8(giz107); doi:
985 10.1093/gigascience/giz107.
- 986 39. Tsilimigras MCB, Fodor AA. Compositional data analysis of the microbiome:
987 fundamentals, tools, and challenges. *Annals of Epidemiology*. 2016;26(5):330-5; doi:
988 10.1016/j.annepidem.2016.03.002.
- 989 40. Aitchison J. The Statistical Analysis of Compositional Data. *Journal of the Royal Statistical*
990 *Society Series B (Methodological)*. 1982;44(2):139-77.

- 991 41. Martín-Fernández JA, Barcelo-Vidal C, Pawlowsky-Glahn V. Dealing with Zeros and
992 Missing Values in Compositional Data Sets Using Nonparametric Imputation.
993 *Mathematical Geology*. 2003;26.
- 994 42. Legendre P, Legendre L. Canonical analysis. In: *Developments in Environmental*
995 *Modelling*. Elsevier; 2012. p. 625-710.
- 996 43. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin P, O'Hara B, et al. *Vegan*:
997 *Community Ecology Package*. R Package Version 2.2-1. 2015;2:1-2.
- 998 44. Rizzo ML, Székely GJ. Energy distance. *Wiley Interdisciplinary Reviews: Computational*
999 *Statistics*. 2016;8(1):27-38; doi: 10.1002/wics.1375.
- 1000 45. Greenacre M. Variable Selection in Compositional Data Analysis Using Pairwise
1001 Logratios. *Mathematical Geosciences*. 2019;51(5):649-82; doi: 10.1007/s11004-018-
1002 9754-x.
- 1003 46. Ernst MD. Permutation Methods: A Basis for Exact Inference. *Statistical Science*.
1004 2004;19(4):676-85; doi: 10.1214/088342304000000396.
- 1005 47. Bastian M, Heymann S, Jacomy M. *Gephi: An Open Source Software for Exploring and*
1006 *Manipulating Networks*. 2009.
- 1007 48. Csardi G, Nepusz T. The *Igraph* Software Package for Complex Network Research.
1008 *InterJournal*. 2005;Complex Systems:1695.
- 1009 49. Anderson MJ. Permutational Multivariate Analysis of Variance (PERMANOVA). In: *Wiley*
1010 *StatsRef: Statistics Reference Online*. American Cancer Society; 2017. p. 1-15.
- 1011 50. Barker M, Rayens W. Partial least squares for discrimination. *Journal of Chemometrics*.
1012 2003;17(3):166-73; doi: <https://doi.org/10.1002/cem.785>.
- 1013 51. Brereton RG, Lloyd GR. Partial least squares discriminant analysis: taking the magic
1014 away. *Journal of Chemometrics*. 2014;28(4):213-25; doi:
1015 <https://doi.org/10.1002/cem.2609>.
- 1016 52. Kalivodová A, Hron K, Filzmoser P, Najdekr L, Janečková H, Adam T. PLS-DA for
1017 compositional data with application to metabolomics. *Journal of Chemometrics*.
1018 2015;29(1):21-8; doi: <https://doi.org/10.1002/cem.2657>.
- 1019 53. Boulesteix A-L, Strimmer K. Partial least squares: a versatile tool for the analysis of high-
1020 dimensional genomic data. *Briefings in Bioinformatics*. 2006;8(1):32-44; doi:
1021 10.1093/bib/bbl016.
- 1022 54. Kuhn M. Building Predictive Models in *R* Using the **caret** Package. *Journal of Statistical*
1023 *Software*. 2008;28(5); doi: 10.18637/jss.v028.i05.
- 1024 55. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. 2 edn: Springer International
1025 Publishing; 2016.
- 1026 56. Fawcett T. An introduction to ROC analysis. *Pattern Recognition Letters*. 2006;27(8):861-
1027 74; doi: 10.1016/j.patrec.2005.10.010.
- 1028 57. Hand DJ, Till RJ. A Simple Generalisation of the Area Under the ROC Curve for Multiple
1029 Class Classification Problems. *Machine Learning*. 2001;45(2):171-86; doi:
1030 10.1023/A:1010920819831.
- 1031 58. Stone M. Cross-Validatory Choice and Assessment of Statistical Predictions. *Journal of*
1032 *the Royal Statistical Society: Series B (Methodological)*. 1974;36(2):111-33; doi:
1033 <https://doi.org/10.1111/j.2517-6161.1974.tb00994.x>.

- 1034 59. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-
1035 source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*.
1036 2011;12(1):77; doi: 10.1186/1471-2105-12-77.
- 1037 60. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
1038 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B*
1039 (Methodological). 1995;57(1):289-300.
- 1040 61. Kumpitsch C, Koskinen K, Schöpf V, Moissl-Eichinger C. The microbiome of the upper
1041 respiratory tract in health and disease. *BMC Biol*. 2019;17(1):87; doi: 10.1186/s12915-
1042 019-0703-z.
- 1043 62. De Boeck I, Wittouck S, Wuyts S, Oerlemans EFM, van den Broek MFL, Vandenheuvel D,
1044 et al. Comparing the Healthy Nose and Nasopharynx Microbiota Reveals Continuity As
1045 Well As Niche-Specificity. *Frontiers in microbiology*. 2017;8:2372-; doi:
1046 10.3389/fmicb.2017.02372.
- 1047 63. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis
1048 and graphics of microbiome census data. *PLoS One*. 2013;8(4):e61217; doi:
1049 10.1371/journal.pone.0061217.
- 1050 64. Rebuli ME, Speen AM, Martin EM, Addo KA, Pawlak EA, Glista-Baker E, et al. Wood
1051 Smoke Exposure Alters Human Inflammatory Responses to Viral Infection in a Sex-
1052 Specific Manner: A Randomized, Placebo-Controlled Study. *Am J Respir Crit Care Med*.
1053 2018; doi: 10.1164/rccm.201807-1287OC.
- 1054 65. Cho Y, Abu-Ali G, Tashiro H, Brown TA, Osgood RS, Kasahara DI, et al. Sex Differences in
1055 Pulmonary Responses to Ozone in Mice. Role of the Microbiome. *Am J Respir Cell Mol*
1056 *Biol*. 2019;60(2):198-208; doi: 10.1165/rcmb.2018-0099OC.
- 1057 66. Yu G, Phillips S, Gail MH, Goedert JJ, Humphrys MS, Ravel J, et al. The effect of cigarette
1058 smoking on the oral and nasal microbiota. *Microbiome*. 2017;5(1):3; doi:
1059 10.1186/s40168-016-0226-6.
- 1060 67. Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo H-S, Villaruz AE, et al. Pathogen
1061 elimination by probiotic *Bacillus* via signalling interference. *Nature*. 2018;562(7728):532-
1062 7; doi: 10.1038/s41586-018-0616-y.
- 1063 68. Liu CM, Price LB, Hungate BA, Abraham AG, Larsen LA, Christensen K, et al.
1064 *Staphylococcus aureus* and the ecology of the nasal microbiome. *Science Advances*.
1065 2015;1(5):e1400216; doi: 10.1126/sciadv.1400216.
- 1066 69. Sakr A, Brégeon F, Mège J-L, Rolain J-M, Blin O. *Staphylococcus aureus* Nasal
1067 Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent
1068 Infections. *Frontiers in microbiology*. 2018;9:2419-; doi: 10.3389/fmicb.2018.02419.
- 1069 70. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. *Curr Pharm*
1070 *Des*. 2009;15(17):1956-73; doi: 10.2174/138161209788453202.
- 1071 71. Casimir GJ, Lefevre N, Corazza F, Duchateau J. Sex and inflammation in respiratory
1072 diseases: a clinical viewpoint. *Biology of sex differences*. 2013;4:16; doi: 10.1186/2042-
1073 6410-4-16.
- 1074 72. Man WH, van Houten MA, Mérelle ME, Vlieger AM, Chu M, Jansen NJG, et al. Bacterial
1075 and viral respiratory tract microbiota and host characteristics in children with lower
1076 respiratory tract infections: a matched case-control study. *Lancet Respir Med*.
1077 2019;7(5):417-26; doi: 10.1016/s2213-2600(18)30449-1.

1078 73. Neumann A, Björck L, Frick I-M. *Fingoldia magna*, an Anaerobic Gram-Positive
1079 Bacterium of the Normal Human Microbiota, Induces Inflammation by Activating
1080 Neutrophils. *Frontiers in Microbiology*. 2020;11(65); doi: 10.3389/fmicb.2020.00065.

1081 74. Hoggard M, Wagner Mackenzie B, Jain R, Taylor MW, Biswas K, Douglas RG. Chronic
1082 Rhinosinusitis and the Evolving Understanding of Microbial Ecology in Chronic
1083 Inflammatory Mucosal Disease. *Clinical Microbiology Reviews*. 2017;30(1):321; doi:
1084 10.1128/CMR.00060-16.

1085 75. Chiu C-Y, Chan Y-L, Tsai M-H, Wang C-J, Chiang M-H, Chiu C-C, et al. Cross-talk between
1086 airway and gut microbiome links to IgE responses to house dust mites in childhood
1087 airway allergies. *Scientific Reports*. 2020;10(1):13449; doi: 10.1038/s41598-020-70528-
1088 7.

1089 76. Bacci G, Paganin P, Lopez L, Vanni C, Dalmastrri C, Cantale C, et al. Pyrosequencing
1090 Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung
1091 Function Decline. *PLoS One*. 2016;11(6):e0156807; doi: 10.1371/journal.pone.0156807.

1092 77. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of
1093 gene expression, enzyme activities, and impact of genetic variation. *Pharmacology &
1094 Therapeutics*. 2013;138(1):103-41; doi:
1095 <https://doi.org/10.1016/j.pharmthera.2012.12.007>.

1096 78. Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome
1097 revealed: sex differences in bidirectional interactions between the microbiota,
1098 hormones, immunity and disease susceptibility. *Semin Immunopathol*. 2019;41(2):265-
1099 75; doi: 10.1007/s00281-018-0716-7.

1100 79. Kim YS, Unno T, Kim BY, Park MS. Sex Differences in Gut Microbiota. *World J Mens
1101 Health*. 2020;38(1):48-60; doi: 10.5534/wjmh.190009.

1102 80. Shin JH, Park YH, Sim M, Kim SA, Joung H, Shin DM. Serum level of sex steroid hormone
1103 is associated with diversity and profiles of human gut microbiome. *Res Microbiol*.
1104 2019;170(4-5):192-201; doi: 10.1016/j.resmic.2019.03.003.

1105 81. Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, et al. Female Sex and
1106 Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological,
1107 Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female
1108 Patients with Lung Disease. *Am J Respir Crit Care Med*. 2018;198(7):850-8; doi:
1109 10.1164/rccm.201801-0168WS.

1110 82. De Boeck I, Wittouck S, Martens K, Claes J, Jorissen M, Steelant B, et al. Anterior Nares
1111 Diversity and Pathobionts Represent Sinus Microbiome in Chronic Rhinosinusitis.
1112 *mSphere*. 2019;4(6):e00532-19; doi: 10.1128/mSphere.00532-19.

1113 83. Chen YW, Li SW, Lin CD, Huang MZ, Lin HJ, Chin CY, et al. Fine Particulate Matter
1114 Exposure Alters Pulmonary Microbiota Composition and Aggravates Pneumococcus-
1115 Induced Lung Pathogenesis. *Front Cell Dev Biol*. 2020;8:570484; doi:
1116 10.3389/fcell.2020.570484.

1117 84. Mariani J, Favero C, Spinazzè A, Cavallo DM, Carugno M, Motta V, et al. Short-term
1118 particulate matter exposure influences nasal microbiota in a population of healthy
1119 subjects. *Environmental research*. 2018;162:119-26; doi: 10.1016/j.envres.2017.12.016.

1120

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [20210721MicrobiomePaperSupplementMicrobiome.docx](#)